What the FDA labels say about taking them together
Aficamten and voriconazole
Aficamten's FDA label of December 16, 2025 names voriconazole in its drug interactions section; the voriconazole labels PlainMeds reads (3) do not name aficamten. The aficamten label: “Fluconazole or Voriconazole Clinical Impact Fluconazole is a moderate CYP2C9 inhibitor, moderate CYP3A inhibitor, and strong CYP2C19 inhibitor. …”
Check it at the source: the aficamten FDA label on DailyMed (effective December 16, 2025, Cytokinetics Inc.); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the aficamten label say about voriconazole?
Aficamten label, drug interactionsFluconazole or Voriconazole Clinical Impact Fluconazole is a moderate CYP2C9 inhibitor, moderate CYP3A inhibitor, and strong CYP2C19 inhibitor. Voriconazole is a strong CYP3A inhibitor, moderate CYP2C19 inhibitor, and weak CYP2C9 inhibitor. Coadministration with fluconazole is observed, and voriconazole is predicted, to increase aficamten exposure, which may increase the risk of developing heart failure due to systolic dysfunction [see Clinical Pharmacology (12.3) ]. Prevention or Management Initiate MYQORZO at 5 mg in patients on stable therapy with fluconazole or voriconazole. …
Aficamten label, warnings and precautionsInitiation of medications that inhibit multiple P450 pathways of MYQORZO elimination (e.g., fluconazole, voriconazole, fluvoxamine) or strong CYP2C9 inhibitors, and discontinuation of moderate-to-strong CYP3A inducers may lead to increased blood concentrations of aficamten and increase the risk of heart failure due to systolic dysfunction [see Contraindications (4), Warnings and Precautions (5.1), and Drug Interactions (7.1) ].
Source: FDA drug label (MYQORZO), Cytokinetics Inc., effective December 16, 2025 (SPL set fd778507-1274-4d1a-a659-5431d55c543a), via openFDA; the full label on DailyMed
What does the voriconazole label say about aficamten?
Voriconazole's label (effective February 26, 2026) and its 2 other brand-application labels do not name aficamten in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aficamten | Voriconazole | |
|---|---|---|
| Labeled for | n/a | Fungal infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once